Genocea Biosciences

Genocea Biosciences

Harnessing the power of T cells.

Other | United States of America | Access to Information |

 Profile Provided By: CSRHub

Overview

Genocea Biosciences created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Their pipeline includes programs addressing herpes simplex virus-2 (HSV-2), pneumococcus, chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. They design their medicines using ATLAS™, their proprietary technology platform. They can recreate in vitro the T cell immune responses of hundreds of humans to thousands of potential antigens to identify a small number of proteins appropriate for testing as product candidates. Their platform has potential to revolutionize vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases.

Industry

Legal Structure

Operating Status

Employees

Other Operating

Funding and Financing Rounds


Team


Impact

Social Objectives:

Environmental Objectives:

Operational Impact:


Impact Reports & Metrics


Offices

Headquarters

100 Acorn Park Drive Floor 5
Cambridge, Massachusetts 02140
United States of America



Explore

Revision History


Quick Search



  • Global  
  • Africa  
  • Americas  
  • Asia  
  • Europe  
  • Oceania  


Incoming

Tags

COPYRIGHT 2017 IMPACTSPACE. ALL RIGHTS RESERVED.